240 related articles for article (PubMed ID: 29692343)
1. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Itzykson R; Duployez N; Fasan A; Decool G; Marceau-Renaut A; Meggendorfer M; Jourdan E; Petit A; Lapillonne H; Micol JB; Cornillet-Lefebvre P; Ifrah N; Leverger G; Dombret H; Boissel N; Haferlach T; Preudhomme C
Blood; 2018 Jul; 132(2):187-196. PubMed ID: 29692343
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
3. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
5. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
6. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
12. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
[TBL] [Abstract][Full Text] [Related]
13. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
14. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH
Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724
[TBL] [Abstract][Full Text] [Related]
15. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
16. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Signal Transduction Pathway Gene Mutations on the One- course Induced Remission Rate and Analysis of Clinical Characteristics in Patients with CBF-AML].
Fan LF; Xu J; Chen XH; Tian TT; Xie J; Hu JJ; Guo ZP; Tan YH; Xu ZF; Ren FG; Zhang YF; Luo M; Ren WX; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):781-788. PubMed ID: 32552936
[TBL] [Abstract][Full Text] [Related]
18. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
19. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
[TBL] [Abstract][Full Text] [Related]
20. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
